相关实验视频

Updated: Jan 18, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG

Published on: March 7, 2017

放射治疗加上新辅助剂和同时进行IL-13Rα2导向免疫毒素治疗,用于扩散性内在庞丁结质瘤

Julian S Rechberger^1,2, Wouter J F Vanbilloen^1,3, Leo F Nonnenbroich^4,5

¹Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.

Communications biology

|January 16, 2026

概括

与IL-13Rα2向免疫毒素GB13相结合的放射疗法在治疗扩散内在质质瘤 (DIPG) 方面显示出前景. 这种组合疗法增强了放射治疗.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
辐射疗法辐射疗法

背景情况:

扩散内在庞丁质瘤 (DIPG) 是一种儿童脑瘤,治疗选择有限.
放射治疗 (RT) 是DIPG的缓解剂.
介素13受体亚单元α2 (IL-13Rα2) 是DIPG中一个有前途的治疗点.

研究的目的:

评估将RT与IL-13Rα2向免疫毒素 (GB13) 结合用于DIPG治疗的疗效.
评估这种综合方法的安全性和耐受性.

主要方法:

使用DIPG细胞系的体外研究和使用DIPG小鼠模型的体内研究.
仅RT与RT加GB13的比较.
评估DNA损伤,亡,细胞活力,增殖,瘤负担和存活率.

主要成果:

在体外,GB13通过抑制DNA损伤修复和调节apoptotic信号来增强RT的疗效.
在老鼠模型中,联合RT和GB13治疗降低了瘤负担和延长了生存时间.
组合疗法被很好地容忍.

结论:

RT加GB13是DIPG的安全有效的治疗策略.
这种组合值得进一步研究,作为DIPG的新型治疗方法.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.